CEPHA s.r.o.
Pilsen, CZ-323 00, Czechia
NCT Number: NCT01197001
Study Design :
* A single center, open, randomized, single dose, two-period, two-treatment, two-sequence, crossover study
Primary Objective:
* To assess the bioequivalence of combination oral formulation of amlodipine/losartan versus two co-administered products containing amlodipine and losartan
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Pilsen, CZ-323 00, Czechia
Secondary Objective:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Amlodipine/Losartan low dose
Amlodipine, Losartan
Time frame: 0-144hrs
Hanmi Pharmaceutical Company Limited
Industry
A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study of Amlodipine and Losartan Versus Two Co-administration of Amlodipine and Losartan in Healthy Caucasian Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details